The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story
The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story
Actavis, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story
A M&A deal was agreed and signed by Watson Pharmaceuticals, a big pharma company, with Uteron Pharma for $150 million in cash up front, and up to $155 million in potential future milestone payments. Read the full story
Watson Pharmaceuticals agreed to sell rights to 18 drugs to win approval from the U.S. Federal Trade Commission for its m&a of Actavis Inc Read the full story
Par Pharmaceutical Companies has entered into pharma partners agreements with two well know big pharma companies, Watson Pharmaceuticals and Actavis Group, respectively,to purchase for cash five generic products that are currently marketed in the U.S. Read the full story
Watson Pharmaceuticals announced the pricing of a debt financing offering of $1.2 billion of 1.875% senior notes due 2017, $1.7 billion of 3.250% senior notes due 2022 and $1.0 billion of 4.625% senior notes due 2042, for a total offering of $3.9 billion in aggregate principal amount. Read the full story
Synthon has entered into a global pharma partners license agreement with Amgen and Watson Pharmaceuticals, for Synthon’s trastuzumab, being developed as a biosimilar to Herceptin, which is currently approved for treatment of breast cancer and gastric cancer.
This report provides all the information you require to better understand Watson and its partnering interests and activities over the past seven years. Read the full story
Watson Pharmaceuticals and Actavis Group jointly announced that Watson has entered into a definitive M&A agreement to acquire privately held Actavis for an upfront payment of EUR4.25 billion Read the full story
Big pharma Watson Pharmaceuticals Inc. (WPI) might announce a deal to buy Actavis for around $6 billion on Wednesday, the Reuters news agency said Monday on its website, citing unnamed sources familiar with the matter Read the full story